^
Association details:
| Biomarker: | FBXW7 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
Excerpt:
CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib....Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies...
DOI:
10.1038/onc.2016.247
Source:
Title:
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
Excerpt:
All 8 FBW7-mutant CRC cell lines were substantially less sensitive to regorafenib compared to 8 FBW7-wild-type (WT) cell lines, as indicated by higher inhibitory concentration 50 (IC50) (Fig. 1B and Table S1).
DOI:
10.1038/onc.2016.247
